<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Voyager Acquisition Corp — News on 6ix</title>
<link>https://6ix.com/company/voyager-acquisition-corp</link>
<description>Latest news and press releases for Voyager Acquisition Corp on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 13 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/voyager-acquisition-corp" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835d0c178dffbe2df11f6b9.webp</url>
<title>Voyager Acquisition Corp</title>
<link>https://6ix.com/company/voyager-acquisition-corp</link>
</image>
<item>
<title>Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG</title>
<link>https://6ix.com/company/voyager-acquisition-corp/news/voyager-acquisition-corporation-announces-approval-of-its-business-combination-with-veraxa-biotech-ag-45</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-acquisition-corp/news/voyager-acquisition-corporation-announces-approval-of-its-business-combination-with-veraxa-biotech-ag-45</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>BROOKLYN, N.Y., March 13, 2026 (GLOBE NEWSWIRE) -- Voyager Acquisition Corporation (NASDAQ: “VACHU,” “VACH,” “VACHW”) (“Voyager” or the “Company”) held the</description>
</item>
<item>
<title>Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG</title>
<link>https://6ix.com/company/voyager-acquisition-corp/news/voyager-acquisition-corporation-announces-redemption-results-in-connection-with-its-business-combination-with-veraxa-biotech-ag</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-acquisition-corp/news/voyager-acquisition-corporation-announces-redemption-results-in-connection-with-its-business-combination-with-veraxa-biotech-ag</guid>
<pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
<description>BROOKLYN, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Voyager Acquisition Corporation (NASDAQ: “VACHU,” “VACH,” “VACHW”) (“Voyager” or the “Company”) today</description>
</item>
<item>
<title>VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC</title>
<link>https://6ix.com/company/voyager-acquisition-corp/news/veraxa-biotech-voyager-acquisition-corp-125500291</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-acquisition-corp/news/veraxa-biotech-voyager-acquisition-corp-125500291</guid>
<pubDate>Thu, 17 Jul 2025 12:55:00 GMT</pubDate>
<description>ZURICH, July 17, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp., a Cayman Islands exempted company and special purpose acquisition company targeting the healthcare sector (NASDAQ:VACH, “Voyager” or the “SPAC”), announced today the filing of a registration statement on Form F-4 (the “Registration Statement”), which includes a preliminary proxy statement, with the U.S. Securities and Exch</description>
</item>
<item>
<title>VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform</title>
<link>https://6ix.com/company/voyager-acquisition-corp/news/veraxa-biotech-to-attend-key-industry-conferences-to-showcase-bitac-technology-platform</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-acquisition-corp/news/veraxa-biotech-to-attend-key-industry-conferences-to-showcase-bitac-technology-platform</guid>
<pubDate>Thu, 29 May 2025 04:00:00 GMT</pubDate>
<description>VERAXA Attending ASCO and BIO with Cantor Fitzgerald, Voyager&apos;s Recently Retained Capital Markets Advisor, and Hosting Meetings with Potential Partners</description>
</item>
<item>
<title>VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer</title>
<link>https://6ix.com/company/voyager-acquisition-corp/news/veraxa-biotech-appoints-rick-austin-as-chief-scientific-officer</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-acquisition-corp/news/veraxa-biotech-appoints-rick-austin-as-chief-scientific-officer</guid>
<pubDate>Tue, 20 May 2025 16:10:00 GMT</pubDate>
<description>Industry Veteran to Support Acceleration of Key Pipeline Projects and Novel BiTAC™ Antibody Formats Towards Clinical StudiesZURICH, May 20, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, “Voyager”), announced today the appointment of Rick Austin, Ph.D. as Chief Scientific Officer, effective May 1st. Dr. Austin brings more than 25 years of leadership ac</description>
</item>
<item>
<title>VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program</title>
<link>https://6ix.com/company/voyager-acquisition-corp/news/veraxa-biotech-enters-co-discovery-alliance-with-omniab-for-a-novel-bispecific-antibody-drug-conjugate-program-1</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-acquisition-corp/news/veraxa-biotech-enters-co-discovery-alliance-with-omniab-for-a-novel-bispecific-antibody-drug-conjugate-program-1</guid>
<pubDate>Mon, 05 May 2025 16:59:00 GMT</pubDate>
<description>Partnership Combines VERAXA's Proprietary ADC Technology with OmniAb's Antibody Discovery Technology for Novel Therapies Targeting Solid TumorsZURICH, SWITZERLAND, May 05, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ: VACH, "Voyager"), announced today a co-discovery alliance with OmniAb, Inc. (NASDAQ: OABI, “OmniAb”) for the development of a novel bispecif</description>
</item>
<item>
<title>VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies</title>
<link>https://6ix.com/company/voyager-acquisition-corp/news/veraxa-biotech-voyager-acquisition-corp-050000947</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-acquisition-corp/news/veraxa-biotech-voyager-acquisition-corp-050000947</guid>
<pubDate>Wed, 23 Apr 2025 05:00:00 GMT</pubDate>
<description>VERAXA’s Novel BiTAC Platform has the Potential to Deliver Multiple Next-Generation Solid Tumor Cancer Therapies, Including Novel Antibody-Drug Conjugate ("ADC") and Bispecific T-cell Engager ("TCE") Candidates, with Strong and Differentiated Clinical ProfilesCompany Pursuing Multiple Strategic Partnerships and Licensing Opportunities in 2025 and 2026Transaction Values VERAXA at a Pre-money Equity Value of $1.3 BillionActively Working with Existing and New VERAXA Investors to Raise a Crossover F</description>
</item>
</channel>
</rss>